Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Daniel Kwon

Pain Medicine Yakima, WA Medical Doctor

NPI 1780645606 CMS profile 126453

1470 N 16Th Ave, Yakima, WA 98902

Open in the dashboard

General payments

$2,142

51 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Daniel Kwon of Yakima, WA is reported in the CMS Open Payments database as having received $2,142 across 51 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 54th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $445 12
2024 General $626 16
2023 General $345 8
2022 General $345 7
2021 General $136 4
2020 General $50 1
2019 General $196 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Kwon
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Daniel Kwon were reported at $445. Among 1,144 Pain Medicine profiles paid that year, the median was $402 and the middle half received between $130 and $1,173.

Show as a table
Year Daniel Kwon Pain Medicine median Middle half National median
2019 $196 $409 $115–$1,311 $163
2020 $50 $214 $66–$666 $114
2021 $136 $299 $84–$899 $132
2022 $345 $335 $103–$1,149 $149
2023 $345 $376 $114–$1,228 $160
2024 $626 $387 $115–$1,173 $164
2025 $445 $402 $130–$1,173 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Nevro Corp. $499 10 payments
  2. Avanos Medical $462 10 payments
  3. Medtronic, Inc. $429 14 payments
  4. SPR Therapeutics, Inc $279 3 payments
  5. Boston Scientific Corporation $260 9 payments
  6. Intuitive Surgical, Inc. $68 1 payment
  7. Nalu Medical, Inc. $67 1 payment
  8. SI-BONE, Inc. $43 1 payment
  9. Pfizer Inc. $22 1 payment
  10. Medtronic USA, Inc. $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,134 50 payments
  2. Consulting Fee $8 1 payment
Products named General payments · program years 2019–2025
  1. INTELLIS ADAPTIVESTIM $402 12 payments
  2. SPRINT PNS System $279 3 payments
  3. Senza $264 6 payments
  4. GENERATOR $256 5 payments
  5. Omnia $130 3 payments
  6. Senza Spinal Cord Stimulation System $106 1 payment
  7. COOLIEF* COOLED RADIOFREQUENCY $105 2 payments
  8. COOLIEF COOLED RADIOFREQUENCY $87 2 payments
  9. General - Pain Management $86 3 payments
  10. Da Vinci Surgical System $68 1 payment
  11. Other $378 14 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 42 drugs

Part D claims

2,021

Median for Physical Medicine and Rehabilitation: 276

Drug cost

$108,947

Median for Physical Medicine and Rehabilitation: $5,921

Branded share of claims

32.8%

Median for Physical Medicine and Rehabilitation: 11.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Fentanyl Generic 54 $17,629
Buprenorphine Generic 49 $16,988
Xtampza Er Oxycodone Myristate Brand 12 $11,668
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 224 $7,774
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 176 $6,190
Oxycontin Oxycodone Hcl Brand 17 $4,733
Movantik Naloxegol Oxalate Brand 11 $4,320
Morphine Sulfate Er Morphine Sulfate Brand 126 $4,309
Hysingla Er Hydrocodone Bitartrate Brand 13 $4,263
Oxycodone Hcl Generic 163 $3,540

The 10 drugs with the highest cost, of 42 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,591 Part D prescribers listed as Physical Medicine and Rehabilitation; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 53 billing codes

Paid by Medicare

$55,532

Medicare's payments for the services billed

Medicare patients

282

Average age 73

Services billed

1,025

160 women, 122 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 70%
Depression 33%
Diabetes 30%
Chronic kidney disease 21%
COPD 20%
Ischemic heart disease 17%
Atrial fibrillation 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

51 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record